← Leaderboards
Ronald Howard Goldstein
Providence Va Medical Center
$4,335,410
Attributed
$4,335,410
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $739.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,593,154 · 6
VA$0 · 2
By mechanism
P50$4,395,556 · 3
R01$2,099,956 · 2
P01$1,097,642 · 1
I01$0 · 2
Top collaborators
- Sharon Irene Smith Rounds8 shared
Most similar at Providence Va Medical Center
Same institution · by research overlap
- Sharon Irene Smith Rounds$16,700,876
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseTumor Necrosis Factor AlphaPulmonary Fibrosis /GranulomaPhosphoric Diester HydrolaseClinical ResearchNitric OxidePhysiologicalEnrollmentHemodynamicsHealth Related Quality Of LifeBlood VesselsDouble-Blind MethodChronicLungDyspneaActivities Of Daily LivingBiological AvailabilityEffective TherapyChronic Obstructive Pulmonary DiseaseGenetically Modified AnimalsHealth Care Service UtilizationCardiopulmonaryEchocardiographyHypoxia
Grant awards (25)
Effect of PDE5 inhibitor on respiratory symptoms in COPD complicated by pulmonaryhypertension$0
I01 · FY2025 · VA
Effect of PDE5 inhibitor on respiratory symptoms in COPD complicated by pulmonaryhypertension$0
I01 · FY2024 · VA
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2019 · VA · contact PI
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2017 · VA · contact PI
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2016 · VA · contact PI
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2015 · VA · contact PI
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2014 · VA · contact PI
Tadalafil for Pulmonary Hypertension Associated with Chronic Lung Disease$0
I01 · FY2013 · VA · contact PI
IL -1 and TNF alpha in the development of COPD$386,383
P01 · FY2006 · HL · contact PI
IL -1 and TNF alpha in the development of COPD$376,423
P01 · FY2005 · HL
Regulation of Collagen Formation in Pulmonary Fibrosis$363,375
R01 · FY2005 · HL
Regulation of Collagen Formation in Pulmonary Fibrosis$363,375
R01 · FY2004 · HL
Regulation of Collagen Formation in Pulmonary Fibrosis$363,375
R01 · FY2003 · HL
EFFECT OF IL-1 AND TNF ON ELASTIN PRODUCTION IN COPD$81,500
R01 · FY2003 · HL
Regulation of Collagen Formation in Pulmonary Fibrosis$363,375
R01 · FY2002 · HL
IL -1 and TNF alpha in the development of COPD$334,836
P01 · FY2002 · HL
EFFECT OF IL-1 AND TNF ON ELASTIN PRODUCTION IN COPD$81,500
R01 · FY2002 · HL
SCOR IN PATHOBIOLOGY OF FIBROTIC LUNG DISEASE$1,651,594
P50 · FY2001 · HL
CORE--ANIMAL$308,594
P50 · FY2001 · HL
TYPE I COLLAGEN REGULATION IN PULMONARY FIBROSIS$308,594
P50 · FY2001 · HL
EFFECT OF IL-1 AND TNF ON ELASTIN PRODUCTION IN COPD$122,250
R01 · FY2001 · HL
SCOR IN PATHOBIOLOGY OF FIBROTIC LUNG DISEASE$1,606,150
P50 · FY2000 · HL
EFFECT OF IL-1 AND TNF ON ELASTIN PRODUCTION IN COPD$361,206
R01 · FY2000 · HL
CORE--ANIMAL$260,312
P50 · FY2000 · HL
TYPE I COLLAGEN REGULATION IN PULMONARY FIBROSIS$260,312
P50 · FY2000 · HL